Advertisement
U.S. markets open in 3 hours 44 minutes

Protalix BioTherapeutics, Inc. (PLX)

NYSE American - NYSE American Delayed Price. Currency in USD
1.5600+0.0700 (+4.70%)
At close: 04:00PM EST
1.5600 0.00 (0.00%)
Pre-Market: 05:11AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close1.4900
Open1.5000
Bid0.0000 x 900
Ask0.0000 x 1800
Day's Range1.5000 - 1.5800
52 Week Range1.2100 - 3.5500
Volume416,936
Avg. Volume302,815
Market Cap113.805M
Beta (5Y Monthly)0.88
PE Ratio (TTM)17.33
EPS (TTM)0.0900
Earnings DateFeb 28, 2024 - Mar 01, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
84% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for PLX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Protalix BioTherapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 10/23/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • PR Newswire

    Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference

    Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced that it will attend and present at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 at the New York Marriott Marquis in New York City.

  • PR Newswire

    Protalix BioTherapeutics Issues 2024 Letter to Stockholders

    Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders.

  • GlobeNewswire

    Levicept Appoints Eliot Forster as CEO

    Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty y